Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave

[1]  C. Berking,et al.  Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition , 2021, Journal for ImmunoTherapy of Cancer.

[2]  E. Robilotti,et al.  Determinants of COVID-19 disease severity in patients with cancer , 2020, Nature Medicine.

[3]  S. Peters,et al.  ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer , 2020, ESMO Open.

[4]  P. Gullón,et al.  Covid-19 and lung cancer: A greater fatality rate? , 2020, Lung Cancer.

[5]  C. Rolfo,et al.  Speeding tumor genotyping during the SARS‐CoV‐2 outbreak through liquid biopsy , 2020, Cancer.

[6]  Alokkumar Jha,et al.  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.

[7]  J. Wolchok,et al.  Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers , 2020, Cancer discovery.

[8]  I. Nagtegaal,et al.  Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands , 2020, The Lancet Oncology.

[9]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[10]  Yan Bai,et al.  Presumed Asymptomatic Carrier Transmission of COVID-19. , 2020, JAMA.

[11]  G. Rossi,et al.  Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. , 2019, Critical reviews in oncology/hematology.

[12]  S. Ellenberg.  Food and Drug Administration (FDA) , 2005 .